

CORRECTION

Open Access



Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis

Katharina Nickel¹, Nicholas J. A. Halfpenny², Sonya J. Snedecor³ and Yogesh Suresh Punekar^{4*}

Correction to: *BMC Infect Dis* 21, 222 (2021)
<https://doi.org/10.1186/s12879-021-05850-0>

Following publication of the original article [1], the authors identified errors in Figs. 3a, b and 4. The correct figures are given below.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1186/s12879-021-05850-0>.

* Correspondence: yogesh.q.punekar@gsk.com

⁴ViiV Healthcare, GSK House, 980 Great West Rd, Brentford, Middlesex TW8 9GS, UK

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.





Fig. 3 Efficacy Results. **a** VS Risk Difference (RE model). **b** CD4 difference (FE model)



Author details

¹Pharmerit International, Berlin, Germany. ²Pharmerit International, Rotterdam, Netherlands. ³Pharmerit International, Bethesda, MD, USA. ⁴ViiV Healthcare, GSK House, 980 Great West Rd, Brentford, Middlesex TW8 9GS, UK.

Published online: 12 April 2021

Reference

1. Nickel K, et al. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infect Dis. 2021;21:222. <https://doi.org/10.1186/s12879-021-05850-0>.